A deadly hantavirus outbreak linked to a cruise ship has sparked widespread concern and a surge in online conspiracy theories. These theories have revived elements of vaccine skepticism that were prevalent during the COVID-19 pandemic, while also fueling false claims about pharmaceutical companies and spreading misinformation about a viral social media “prediction.” The situation highlights how early-stage biomedical research can be misinterpreted, influencing public perceptions of vaccine development and shaping views on health risks associated with hantavirus.
The outbreak has drawn attention to the Andes hantavirus strain, which has been confirmed by the World Health Organization as the cause of the cases linked to the Dutch cruise ship MV Hondius. Three passengers have died, and another remains in intensive care at a South African hospital. This has led to heightened interest in hantavirus, especially as researchers continue their preclinical work and health officials monitor the situation closely.
Moderna’s Hantavirus Work Explained
The online speculation is connected to a legitimate but early-stage research project announced in 2024 between Korea University’s Vaccine Innovation Center and Moderna. The initiative focuses on hantaviruses that cause Hemorrhagic Fever with Renal Syndrome (HFRS), a form of the disease found primarily in East Asia and parts of Europe. This research is part of Moderna’s mRNA Access Program, which provides technical support and materials to outside researchers.
It is important to note that this effort is still in the preclinical stage, meaning it has not yet entered human testing and is not part of any approved or planned vaccination program. The project does not target the Sin Nombre virus, the strain most commonly associated with U.S. cases, and there is currently no approved hantavirus vaccine available in the United States.
Hantavirus is not a single virus but a family of related viruses, with different strains circulating in Asia, Europe, and the Americas. Vaccines targeting one strain may not offer protection against others.
“Researchers have worked on hantavirus vaccines for decades, but earlier candidates were less effective against some European strains. Moderna’s vaccine is designed to provide broader protection across multiple strains,” said Luis Marcos, an infectious disease expert at Stony Brook Medicine in New York. “This is a normal part of scientific progress: vaccines are continually improved as researchers learn more about viruses and immune responses.”
Old “Prediction” Circulates Again
In addition to the research, viral social media posts have revived a years-old “prediction” about a hantavirus outbreak in 2026. An X account known as “iamasoothsayer” posted in June 2022: “2023: Corona ended 2026: Hantavirus.” The post has since gained over 255,000 likes, 100,000 reposts, and 21,000 replies following the cruise ship outbreak. The X user, who describes themselves as an “Astrologist,” has claimed to “read the future.”
Social Media Reaction and Political Framing
Despite the limited scope of the research, Moderna’s work has been framed online as evidence of a broader vaccine agenda. Some individuals have suggested that the timing of the research indicates advance knowledge of outbreaks. For example, former Representative Marjorie Taylor Greene wrote on X: “They manipulate the virus (bioweapon), make the vaccine (poison), and then make the profits because they own the vast majority of your elected leaders.”
Other commentators have pointed to the timing of the research, suggesting it indicates advance knowledge of outbreaks. Jordan Crowder, host of the Conscious Observers Podcast, wrote: “Luckily 2 years ago, Moderna started working on a vaccine for Hantavirus. They just have the best foresight…”
Cruise Ship Outbreak Fuels Public Attention
The resurgence of these claims has coincided with a sharp increase in public discussion of hantavirus following the MV Hondius outbreak. At least five passengers have been identified as infected with the Andes virus, a strain typically found in South America. The deadly cases have drawn global attention because hantavirus outbreaks are rare and often localized.
Hantavirus infections in the United States remain uncommon, with only 890 cases reported between 1993 and 2023, according to the Centers for Disease Control and Prevention. The virus is typically spread through exposure to infected rodent droppings or saliva, and the strains that circulate vary widely by region.
What Happens Next
From Korea University’s announcement, Moderna’s role is limited to providing mRNA materials and technical support under its mRNA Access Program, which helps researchers in other countries explore vaccines for emerging or neglected infectious diseases. The hantavirus vaccine candidates involved are preclinical, meaning they have not entered human trials and face significant funding and regulatory hurdles before that could happen.
